Página principal > Artículos > Bowel preparation for colonoscopy changes serum composition as detected by thermal liquid biopsy and fluorescence spectroscopy
Resumen: (1) Background: About 50% of prescribed colonoscopies report no pathological findings. A secondary screening test after fecal immunochemical test positivity (FIT+) would be required. Considering thermal liquid biopsy (TLB) as a potential secondary test, the aim of this work was to study possible interferences of colonoscopy bowel preparation on TLB outcome on a retrospective study; (2) Methods: Three groups were studied: 1/514 FIT(+) patients enrolled in a colorectal screening program (CN and CP with normal and pathological colonoscopy, respectively), with blood samples obtained just before colonoscopy and after bowel preparation; 2/55 patients from the CN group with blood sample redrawn after only standard 8–10 h fasting and no bowel preparation (CNR); and 3/55 blood donors from the biobank considered as a healthy control group; (3) Results: The results showed that from the 514 patients undergoing colonoscopy, 247 had CN and 267 had CP. TLB parameters in these two groups were similar but different from those of the blood donors. The resampled patients (with normal colonoscopy and no bowel preparation) had similar TLB parameters to those of the blood donors. TLB parameters together with fluorescence spectra and other serum indicators (albumin and C-reactive protein) confirmed the statistically significant differences between normal colonoscopy patients with and without bowel preparation; (4) Conclusions: Bowel preparation seemed to alter serum protein levels and altered TLB parameters (different from a healthy subject). The diagnostic capability of other liquid-biopsy-based methods might also be compromised. Blood extraction after bowel preparation for colonoscopy should be avoided. Idioma: Inglés DOI: 10.3390/cancers15071952 Año: 2023 Publicado en: Cancers 15, 7 (2023), 1952 [16 pp.] ISSN: 2072-6694 Factor impacto JCR: 4.5 (2023) Categ. JCR: ONCOLOGY rank: 78 / 322 = 0.242 (2023) - Q1 - T1 Factor impacto CITESCORE: 8.0 - Oncology (Q1) - Cancer Research (Q2)